Consumptive hypothyroidism complicating infantile hepatic hemangioma successfully treated with propranolol: a case report and literature review

doi:10.21203/rs.3.rs-3404894/v1

Download PDF

Research Article

Consumptive hypothyroidism complicating infantile hepatic hemangioma successfully treated with propranolol: a case report and literature review

https://doi.org/10.21203/rs.3.rs-3404894/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

consumptive hypothyroidism (CH) is a rare paraneoplastic syndrome, caused by the overexpression in vascular tumors of type 3 deiodinase (D3), converting thyroid hormones into inactive metabolites.

Case presentation

We report the case of a 2-months-old male infant with diffuse infantile hepatic hemangioma (IHH). Thyroid function screening detected a CH. The patient was promptly treated with propranolol: after 2 weeks, a marked reduction in tumour size was observed and thyroid function was restored. No hormone replacement therapy was required. We then performed a literature review on PubMed/Medline: based on the title and abstract, we extracted 64 cases of CH secondary to IHH published between 2000 and 2023. 59.37% patients received propranolol, either alone (52.63%) or in combination with other treatments. 18.75% patients required surgical treatment or liver transplant. LT4 was administered in 92.85% of the patients. Patients who received propranolol required a lower dosage of LT4 than patients who received other treatments.

Conclusions

thyroid function should be evaluated in all children with IHH to rule out CH. Early recognition of IHH and CH and prompt therapy with propranolol can effectively treat IHH and the subsequent hypothyroidism, sometimes even without the need of hormone replacement therapy.

Case Report

Consumptive hypothyroidism

Infantile hepatic hemangioma

Propranolol

Thyroid hormones

Infantile hemangioma (IH) is a vascular neoplasm characterized by abnormal proliferation of endothelial cells and aberrant blood vessels architecture. (1) IH is the most common benign tumors of childhood, occurring in about 5% of children. (2) The neoplasm probably develops from placental stem cells embolized during early fetal life to tissues where placenta-like growth is possible, such as the skin and the liver. IH usually appears before 4 weeks of age and then shows a rapid growth up to 12 months of age, followed by a slow involution phase. A minority of cutaneous IHs are potentially problematic, due of their size or position. (3–6) Infantile hepatic hemangioma (IHH) is the most common visceral IH, and typically occurs in patients with multiple cutaneous IH. (2, 7) Diffuse IHH has a significant morbidity and mortality due to complications such as hepatomegaly and abdominal compartment syndrome. (1, 6, 8–10)

A recently identified paraneoplastic syndrome, defined consumptive hypothyroidism (CH), can complicate diffuse IHH. (11) CH results from the over-expression in the endothelium of vascular neoplasm of iodothyronine deiodinase type 3 (D3), which converts thyroid hormones into inactive metabolites: T4 into reverse T3 (rT3) and T3 into T2. D3 is physiologically expressed in fetal tissues and in the placenta, having the role of protecting the fetus from excesses of thyroid hormones, while during extrauterine life its expression is limited. CH due to D3 overexpression is characterized by increased TSH and rT3 levels, with normal or low fT4 and fT3. (12)

After the serendipitous observation of the usefulness of propranolol in reducing the size of cutaneous IH (13), propranolol has become the treatment of choice for cutaneous IH (2, 14) and has been increasingly used for the treatment of IHH. (10, 15–17) Propranolol acts by inducing vasoconstriction and inhibition of angiogenesis. (1) It is a safe and effective therapy, with rare side effects. (18, 19)

CH is treated with substitutive therapy: the required replacement dose of levothyroxine (LT4) is usually much higher than the replacement dose in congenital hypothyroidism, due to massive peripheral conversion to inactive forms. In severe cases, therapy with liothyronine can be associated. (12)

We report a case of IHH complicated by CH, completely recovered after treatment with oral propranolol without the need of thyroid hormone replacement. We also perform a literature review on CH-complicated IHH to evaluate existing cases, proposed treatments, as well as follow up and outcomes. We searched PubMed and Medline databases for studies published between 2000 and 2023 about IHH and CH. The complete search items were: (children OR child OR infant OR infantile OR pediatric OR paediatric OR newborn) AND (hepatic hemangioma* OR hepatic haemangiom* OR hemangioendotheliom* OR haemangioendotheliom* OR haemangiom* OR hemangiom*) AND (consumptive hypothyroidism OR hypothyroidism). References within the included articles were then reviewed and additional case reports were identified. Only articles in English were accepted. Two reviewers independently selected articles by title, abstract and full paper review. We included 46 case reports or case series, for a total of 64 patients with IHH complicated by CH. Demographic, clinical, laboratory and radiological, treatment and outcome data were collected for all articles matching the criteria on an electronic spreadsheet. Data were extracted by one reviewer and checked by a second.

A 2-month-old male infant was referred to our Centre in April 2020 because of poor feeding and failure to thrive. The baby was born at 36 weeks of gestational age after a normal pregnancy, one of two twins conceived through egg donation. His birth weight was 2120 g (< 3rd percentile). Prenatal ultrasounds were normal and his twin was healthy. Neonatal screening for TSH level was normal (TSH 2.71 microU/ml, n.v. < 10). From two weeks of age the patient was irritable after meals, with frequent regurgitations and emission of liquid and malodorous stools 6–7 times/day.

On first examination, the child was pale and 10 small cutaneous IHs (diameter < 5mm) were observed on

the face, chest wall, back and limbs; the parents reported that they had grown in size since birth. (Fig. 1) The remainder of the physical examination was normal. His weight was 3390g (< 3rd percentile). The blood test revealed normocytic anemia, a slight electrolyte imbalance with a Na level of 134 mmol/L, normal renal and hepatic function, and elevated alfa-fetoprotein. Cardiac function was normal. We suspected IHH, so abdominal ultrasound and MRI were performed and showed marked hepatomegaly with diffuse nodules with a maximum diameter of 20 mm with nearly total replacement of the hepatic parenchyma, indicative of diffuse IHH. (Figs. 2 and 3) To rule out a CH, thyroid function was tested: TSH, fT4, fT3 and rT3 values at diagnosis and during follow-up are shown in Table 1. A normal in situ gland showed at ultrasound and the absence of thyroid auto-antibodies ruled out other forms of hypothyroidism. We began therapy with oral propranolol at an initial dose of 1 mg/Kg with subsequent dose escalation to 2 mg/kg after five days. The treatment was well tolerated with no documented side effects. No thyroid hormone replacement therapy was required as after two weeks of therapy, TSH level normalized. After 1 month of therapy, ultrasound showed a marked reduction of the hepatic lesions. After 1 year, liver and skin hemangiomas were no longer observable and TSH remained normal, so we discontinued oral propranolol.

Table 1

Thyroid blood tests of our case at diagnosis, after 14 days and 30 days of propranolol therapy
	Normal value for age	At diagnosis (2 months of age)	After 14 days of therapy	After 30 days of therapy
TSH (microU/ml)	0.25-5	33.05	5	1.88
fT4 (pg/ml)	5.5–15	16.8	13.9	10.8
fT3 (pg/ml)	2.4-5	3.7	3.1	3.3
rT3 (ng/ml)	0.5–0.95	2	0.67	--

The demographic and clinical features of the cases identified in our literature review are shown in Table 2.

Table 2

Review of case reports and case series reporting children with consumptive hypothyroidism due to infantile hepatic hemangioma (2000–2023).
CASE N.	AUTHOR, YEAR	Sex	Age at diagnosis (months)	Outco me	TSH at diagnos is (mU/L)	IHH Therapy	LT4 therapy	LT4 max dosage (mcg/kg/ die) *	Liothyron ine therapy
1	Huang, 2000 (11)	M	1.5	Dead	177	St–Int-Sur	Yes	7.6	Yes
2	Mason, 2001 (23)	M	1.75	Alive	203	St-Int-Sur	Yes	7	Yes
3	Ayling, 2001 (24)	F	2	Dead	103	Tr	Yes	°	No
4	Ayling, 2001 (24)	M	0.3	Alive	35	Tr	Yes	°	No
5	Ayling, 2001 (24)	M	1.25	Alive	200	Sur	Yes	°	No
6	Ayling, 2001 (24)	F	4	Alive	475	Sur	Yes	°	No
7	Ayling, 2001 (24)	F	4	Alive	16	Sur	°	°	°
8	Ayling, 2001 (24)	F	4	Alive	°	Sur	°	°	°
9	Ayling, 2001 (24)	M	5	Alive	40	Sur	°	°	°
10	Ayling, 2001 (24)	M	0.5	Dead	°	Sur	°	°	°
11	Konrad, 2003 (25)	M	2	Alive	100	Pr	Yes	28	No
12	Güven, 2005 (26)	F	0	Alive	100	St	Yes	19.8	Yes
13	Ho, 2005 (27)	F	2.5	Alive	90	St	Yes	°	Yes
14	Lee, 2006 (28)	F	1.5	Alive	182	St-Vin-Int- Cyc-Tr	Yes	15	No
15	Balazs, 2007 (29)	F	1.5	Alive	182	St–Int–Tr	Yes	75	Yes
16	Kalpatthi, 2007 (30)	M	4	Alive	53.3	St	Yes	°	No
17	Cho, 2008 (31)	M	7	Alive	18.98	St–Vin	Yes	5.4	No
18	Mouat, 2008 (32)	F	0.75	Alive	17	St	Yes	25	No
19	Çetinkaya, 2010 (33)	M	0	Alive	150	St – Int	Yes	22	Yes
20	Peters, 2010 (34)	M	1	Alive	66.2	St – Vin	Yes	20	Yes
21	Bessho, 2010 (35)	F	0	Alive	45.2	St – Int – Sur	Yes	7.5	No
22	Mazereeuw-Hautier, 2010 (15)	°	°	Alive	°	Pr	°	°	No
23	Mazereeuw-Hautier, 2010 (15)	°	°	Alive	°	Pr – St – Vin	°	°	No
24	Mazereeuw-Hautier, 2010 (15)	°	°	Alive	°	Pr – St	°	°	No
25	Marsciani, 2010 (16)	F	2	Alive	33.8	Pr – St – Vin - Cyc	Yes	1	No
26	Jassam, 2011 (36)	M	2	Dead	138	St – Int – Sur	Yes	10	No
27	Yeh, 2011 (37)	F	1.5	Alive	68	St – Vin	Yes	°	Yes
28	Yeh, 2011 (37)	M	1	Alive	19.8	St – Vin	No	-	No
29	Yeh, 2011 (37)	M	1	Alive	31.4	Pr – St	Yes	°	No
30	Yeh, 2011 (37)	F	0.5	Alive	55.8	Pr – St – Vin	Yes	°	Yes
31	Imteyaz, 2011 (38)	F	4	Alive	14.2	St	Yes	°	Yes
32	Mhanna, 2011 (39)	F	1.5	Alive	9.47	Pr	Yes	°	No
33	Mhanna, 2011(39)	M	3	Alive	°	Pr	Yes	°	No
34	Vergine, 2012 (17)	F	2	Alive	40	Pr – St – Vin	Yes	2	No
35	Avagyan, 2013 (40)	F	0.5	Alive	65.1	Pr	Yes	30	No
36	Wijeratne, 2014 (41)	M	1.5	Alive	37.7	Pr – St	Yes	16	No
37	Sun, 2014 (42)	F	0.5	Dead	°	St	Yes	°	No
38	Wasserman, 2015 (43)	F	2	Alive	123	Pr – St – Vin	Yes	21	Yes
39	Emir, 2016 (44)	F	0.5	Dead	74.2	Pr – St	Yes	18.5	No
40	Özdemir, 2017 (45)	M	4	Alive	177	Pr – St	Yes	°	No
41	Takai, 2017 (46)	M	0.25	Alive	54.7	Pr – St	Yes	°	No
42	Weber Pasa, 2017 (47)	F	0	Alive	24	Vin	Yes	110	Yes
43	Al Tasseh, 2017 (48)	M	3.5	Alive	220	Pr	Yes	25	No
44	Nguyen, 2017 (49)	M	2	Alive	54	Pr	No	-	No
45	Higuchi, 2017 (50)	M	2	Alive	17.7	Pr	No	-	Yes
46	Campbell, 2018 (51)	F	0.5	Alive	115.4	Pr	Yes	9.6	No
47	Simsek, 2018 (52)	M	4	Alive	177	Pr – St	Yes	35	No
48	Igarashi, 2018 (53)	M	0	Alive	153	Pr	Yes	12.5	No
49	Al-Ghamdi, 2018 (54)	M	2	Alive	281	Pr	Yes	9.6	No
50	Acharya, 2019 (55)	F	0.5	Alive	100	Pr – St	Yes	25	No
51	Osada 2019 (56)	M	4	Alive	561	Pr	Yes	13	Yes
52	Yang, 2019 (57)	F	26	Dead	°	Pr - St – Vin	Yes	°	No
53	Yang, 2019 (57)	F	1.5	Alive	°	Pr	Yes	°	No
54	Yang, 2019 (57)	F	1.8	Alive	°	Pr	Yes	°	No
55	Kim, 2020 (58)	M	1	Alive	100	Pr – St	Yes	7	No
56	Joshi, 2020 (59)	F	3	Alive	75	Pr – St – Int	Yes	33	Yes
57	Verma, 2020 (60)	F	4	Alive	17.5	Pr	Yes	9.1	No
58	Zheng, 2021 (61)	F	2	Alive	150	Pr	Yes	20	No
59	Siano, 2022 (20)	F	3	Alive	58.7	Pr	Yes	10	No
60	Siano, 2022 (20)	M	1	Alive	36.7	Pr	Yes	12	No
61	Siano, 2022 (20)	M	6	Alive	60.7	Pr - Sur	Yes	15	No
62	Numazawa, 2022 (62)	M	1	Alive	63.9	Pr - St	Yes	7.5	Yes
63	Morais, 2023 (63)	F	3	Alive	27.1	Pr	Yes	°	No
64	Our case	M	1.5	Alive	33.5	Pr	No	-	No

31 out of 64 (48.43%) of patients are female and the median age at diagnosis is 2 months. Death is reported in 7/64 patients (10.93%). The laboratory profile shows very high TSH levels at diagnosis, with a mean value of 145.5 mU/L. As regards the tumor-directed therapy, the use of different treatments is reported including corticosteroids, interferon, vincristine, cyclophosphamide, propranolol, surgery and liver transplantation. 38/64 patients (59.37%) received propranolol, either alone (20/38, 52.63%) or in combination with other treatments. 12/64 patients (18.75%) underwent surgical treatment or liver transplant.

Treatment of hypothyroidism consisted in the administration of LT4 and/or liothyronine. Among the 56 patients for whom we have data regarding the therapy, 52/56 (92.85%) received LT4. The mean maximum dose of LT4 alone was 24.04 mcg/kg/die; reported dosages ranged between 1 and 110 mcg/kg/d. The association of liothyronine was required in 15/52 (28.8%) patients. In 1 case, only liothyronine was used (Table 2, case n.45)

[Table – SEE END OF THE DOCUMENT]

IHH is a visceral neoplasm, often associated with cutaneous IH, which can lead to serious and fatal complications. Early diagnosis of IHH allows for rapid initiation of therapy and reduces IHH mortality. The American Academy of Pediatrics recommends screening with abdominal ultrasound any child with 5 or more cutaneous IH to rule out visceral involvement. (2) Abdominal ultrasound can also be considered in children with fewer than 5 cutaneous IH, especially if associated with systemic impairment (20), even though a cut-off of 5 cutaneous IH has recently been confirmed to be the most appropriate threshold for abdominal ultrasonography screening. (21)

Virtually all diffuse IHH can cause CH, with variable severity depending on the extension of the neoplasm.

(1)Thyroid abnormalities may not be present at the time of neonatal screening as they occur when the neoplasm grows in the first few weeks of life. For this reason, we recommend investigating thyroid function in all infants with IHH, given the critical role of thyroid hormones in the development of the central nervous system in the first years of life.

Our review shows an increasing use of propranolol in the treatment of IHH, which is in fact supported by

literature data regarding the efficacy of propranolol in reducing IHH size and complications.(10, 15–17) Traditional medical treatments for IHH (systemic corticosteroids, chemotherapy, hepatic surgery or liver transplantation) are of inconsistent efficacy and cause significant side effects.(1, 17) As evidence of this, among the reviewed cases, most of the patients requiring surgery or liver transplantation were diagnosed before 2011 and were not treated with propranolol. Also, the number of patients who died due to IHH complications is higher among those not treated with propranolol (5 vs 2).

LT4 replacement therapy in CH often consists of very high doses of LT4, and in severe cases of the use of liothyronine in combination has been proposed. (12) This is due to the peripheral conversion to inactive forms (rT3) by Deiodinase 3, overexpressed in the hemangioma endothelium. Indeed, the reviewed cases received a mean dose of LT4 of 24.04 mcg/kg/day (range 1-110 mcg/kg/day), higher than the dose of 10–15 mcg/Kg/day usually adopted for primary congenital hypothyroidism. (22)

An important observation regarding the treatment of CH is that patients who received propranolol required a mean dose of LT4 of 18.31 mcg/kg/d to correct hypothyroidism, while patients who received other treatments required higher doses of LT4, with a mean dose of 35.5 mcg/d. This suggests that propranolol not only effectively treats IHH, but also helps restore the euthyroid state by reducing tumor size. Moreover, 4 patients out of 64 (6.25%), including our case, did not require any hormone replacement treatment. These patients were all aged less than or equal to 2 months at diagnosis. This suggests that early recognition of the IHH and prompt start of propranolol therapy can effectively treat subsequent CH without the need for hormone replacement therapy. Obviously, it is essential to follow the patient with a close endocrinological follow-up.

In the presence of 5 or more cutaneous hemangiomas, an abdominal ultrasound is recommended to rule out liver involvement. When the diagnosis of IHH is confirmed, it is important to test thyroid function to promptly diagnose CH. Early therapy with propranolol reduces hepatic lesions and the occurrence of possible complications. Furthermore, it may allow to avoid the need for hormone replacement therapy. In the case of CH, careful monitoring of thyroid function is essential, and hormonal replacement therapy should be started when necessary.

CH (Consumptive hypothyroidism), D3 (type 3 deiodinase), IH (Infantile hemangioma), IHH (Infantile hepatic hemangioma)

Acknowledgement

We gratefully acknowledge the help of the medical staff of the Pediatric Unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna in the clinical investigations and care of the patient.

Ethics approval and consent to participate

No ethics approval was required from Independent Ethics Committee of the Area Vasta Emilia Centro (CE-AVEC) for the type of report. Written informed consent to participate was provided by the patient’s parents. The study was conducted in accordance with the ethical standards as laid down in the Declaration of Helsinki and its later amendments. Personal data were restricted to essential information and were treated in order to guarantee the respect of the privacy of the involved patient.

Consent for publication

The family gave written consent for publication of all clinical information and images relating to the case.

Conflict of Interest Statement

The authors of this manuscript have no conflict of interest to declare.

Funding Sources

None.

Author Contributions

IB and GP were responsible for acquisition and interpretation of data, as well as drafting the manuscript. AC, AP, AR, VDN, MG and ML were responsible for overseeing and revising the manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Darrow DH, Greene AK, Mancini AJ, Nopper AJ, Cohen BA, Antaya RJ, et al. Diagnosis and management of infantile Hemangioma. Pediatrics. 2015;136(4):e1060–104.
Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1).
Itinteang T, Withers AHJ, Davis PF, Tan ST. Biology of Infantile Hemangioma. Vol. 1, Front Surg. 2014.
Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics. 2008;122(2):360–7.
North PE, Waner M, Mizeracki A, Mihm MC. GLUT1: A newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11–22.
Iacobas I, Phung TL, Adams DM, Trenor CC, Blei F, Fishman DS, et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring. J Pediatr. 2018;203:294–300e2.
Horii KA, Drolet BA, Frieden IJ, Baselga E, Chamlin SL, Haggstrom AN, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2011;28(3):245–53.
Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: Subtype classification. J Pediatr Surg. 2012;47(1):165–70.
Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Pediatr Surg. 2007;42(1):62–8.
Rialon KL, Murillo R, Fevurly RD, Kulungowski AM, Christison-Lagay ER, Zurakowski D et al. Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. In: Journal of Pediatric Surgery. 2015. p. 837–41.
Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HPW et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. 2000;185–9.
Luongo C, Trivisano L, Alfano F, Salvatore D. Type 3 deiodinase and consumptive hypothyroidism: A common mechanism for a rare disease. Vol. 4, Frontiers in Endocrinology. 2013.
Léauté-Labrèze C, De La Roque ED, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.
Lou Y, Peng WJ, Cao Y, Cao DS, Xie J, Li HH. The effectiveness of propranolol in treating infantile haemangiomas: A meta-analysis including 35 studies. Br J Clin Pharmacol. 2014;78:44–57.
Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr. 2010;157(2):340–2.
Marsciani A, Pericoli R, Alaggio R, Brisigotti M, Vergine G. Massive response of severe infantile hepatic hemangioma to propanolol. Vol. 54, Pediatric Blood and Cancer. 2010. p. 176.
Vergine G, Marsciani A, Pedini A, Brocchi S, Marsciani M, Desiderio E, et al. Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma. Horm Res Paediatr. 2012;78(4):256–60.
Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE et al. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. In: Pediatrics. 2013. p. 128–40.
De Graaf M, Breur JMPJ, Raphaël MF, Vos M, Breugem CC, Pasmans SGMA. Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants. J Am Acad Dermatol. 2011;65(2):320–7.
Siano MA, Ametrano O, Barbato F, Sammarco E, Ranucci G, Pietrobattista A et al. Consumptive Hypothyroidism due to Hepatic Hemangiomas: A Case Series and Review of the Literature. JPGN Rep. 2022;3(4).
Ji Y, Chen S, Yang K, Xiang B, Jiang X, Xu X et al. Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: A multicenter prospective study. J Am Acad Dermatol. 2021;84(5).
Van Trotsenburg P, Stoupa A, Léger J, Rohrer T, Peters C, Fugazzola L et al. Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update - An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology. Vol. 31, Thyroid. Mary Ann Liebert Inc.; 2021. p. 387–419.
Mason KP, Koka BV, Eldredge EA, Fishman SJ, Burrows PE. Perioperative considerations in a hypothyroid infant with hepatic haemangioma. Paediatr Anaesth. 2001;11(2):228–32.
Ayling RM, Davenport M, Hadzic N, Metcalfe R, Buchanan CR, Howard ER, et al. Hepatic hemangioendothelioma associated with production of humoral thyrotropin-like factor. J Pediatr. 2001;138(6):932–5.
Konrad D, Ellis G, Perlman K. Associated With Multiple Liver Hemangiomas. Pediatrics. 2003;112(6):1424–6.
Güven A, Aygun C, Ince H, Aydin M, Pinarli FG, Baysal K, et al. Severe hypothyroidism caused by hepatic hemangioendothelioma in an infant of a diabetic mother. Horm Res. 2005;63(2):86–9.
Ho J, Kendrick V, Dewey D, Pacaud D. New insight into the pathophysiology of severe hypothyroidism in an infant with multiple hepatic hemangiomas. J Pediatr Endocrinol Metab. 2005;18(5):511–4.
Lee TC, Barshes NR, Agee EE, O’Mahony CA, Karpen SJ, Carter BA, et al. Resolution of medically resistant hypothyroidism after liver transplantation for hepatic hemangioendothelioma. J Pediatr Surg. 2006;41(10):1783–5.
Balazs AE, Athanassaki I, Gunn SK, Tatevian N, Huang SA, Haymond MW, et al. Case report: Rapid resolution of consumptive hypothyroidism in a child with hepatic hemangioendothelioma following liver transplantation. Ann Clin Lab Sci. 2007;37(3):280–4.
Kalpatthi R, Germak J, Mizelle K, Yeager N. Thyroid abnormalities in infantile hepatic hemangioendothelioma. Pediatr Blood Cancer. 2007;49(7):1021–4.
Cho YH, Taplin C, Mansour A, Howman-Giles R, Hardwick R, Lord D, et al. Case report: Consumptive hypothyroidism consequent to multiple infantile hepatic haemangiomas. Curr Opin Pediatr. 2008;20(2):213–5.
Mouat F, Evans HM, Cutfield WS, Hofman PL, Jefferies C. Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J Pediatr Endocrinol Metab. 2008;21(7):701–3.
Çetinkaya S, Kendirci HNP, Ag̀ladog̀lu SY, Baş VN, Özdemir S, Bozkurt C, et al. Hypothyroidism due to hepatic hemangioendothelioma: A case report. JCRPE J Clin Res Pediatr Endocrinol. 2010;2(3):126–30.
Peters C, Langham S, Mullis PE, Dattani MT. Use of combined liothyronine and thyroxine therapy for consumptive hypothyroidism associated with hepatic haemangiomas in infancy. Horm Res Paediatr. 2010;74(2):149–52.
Bessho K, Etani Y, Ichimori H, Miyoshi Y, Namba N, Yoneda A, et al. Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr. 2010;169(2):215–21.
Jassam N, Visser TJ, Brisco T, Bathia D, McClean P, Barth JH. Consumptive hypothyroidism: A case report and review of the literature. Ann Clin Biochem. 2011;48(2):186–9.
Yeh I, Bruckner AL, Sanchez R, Jeng MR, Newell BD, Frieden IJ. Diffuse infantile hepatic hemangiomas: A report of four cases successfully managed with medical therapy. Pediatr Dermatol. 2011;28(3):267–75.
Imteyaz H, Karnsakul W, Levine MA, Burrows PE, Benson J, Hsu S, et al. Unusual case of hypothyroidism in an infant with hepatic hemangioma. J Pediatr Gastroenterol Nutr. 2012;54(5):692–5.
Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol - A case series. Pediatr Dermatol. 2011;28(1):39–45.
Avagyan S, Klein M, Kerkar N, Demattia A, Blei F, Lee S, et al. Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma. J Pediatr Gastroenterol Nutr. 2013;56(3):e17–20.
Wijeratne NG, Kao KT, Simm PJ, Doery JCG. A baby boy with hypothyroidism and hemangioendothelioma. Clin Chem. 2014;60(6):818–21.
Sun J, Karmazyn B, Lin J, Faught PR, Fan R, Saxena R. Newborn with an underrecognized triad: Skin lesion, abdominal distention, and hypothyroidism. J Pediatr. 2014;164(2):419–20.
Wasserman JD, Mahant S, Carcao M, Perlman K, Pope E. Vincristine for successful treatment of steroid-dependent infantile hemangiomas. Pediatrics. 2015;135(6):e1501–5.
Emir S, Ekici F, İkiz MA, Vidinlisan S. The association of consumptive hypothyroidism secondary to hepatic hemangioma and severe heart failure in infancy. Turk Pediatri Ars. 2016;51(1):52–6.
Özdemir ZC, Düzenli Kar Y, Şöhret NC, Kebapçı M, Bör Ö. Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma. Drug Discov Ther. 2017;11(3):161–4.
Takai A, Iehara T, Miyachi M, Okumura Y, Hasegawa T, Tokuda S et al. Successful treatment of a hepatic-hemangioendothelioma infant presenting with hypothyroidism and tetralogy of Fallot. Pediatr Neonatol [Internet]. 2018;59(2):216–8. https://doi.org/10.1016/j.pedneo.2017.08.002.
Weber Pasa M, Selbach Scheffel R, Borsatto Zanella A, Maia AL, Dora JM. Consumptive Hypothyroidism: Case Report of Hepatic Hemangioendotheliomas Successfully Treated with Vincristine and Systematic Review of the Syndrome. Eur Thyroid J. 2017;6(6):321–7.
Al Tasseh F, El-Khansa M, Abd O, Abdel Khalek A, El-Rifai N. Diffuse hepatic hemangioma with single cutaneous hemangioma: an alerting occurrence. Clin Case Rep. 2017;5(6):887–90.
Nguyen T, Orchard D, Zacharin M. Liver haemangiomas and consumptive hypothyroidism in association with three cutaneous haemangiomas. J Paediatr Child Health. 2017;53(12):1226–8.
Higuchi S, Takagi M, Hasegawa Y. Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. Endocr J. 2017;64:639–43.
Campbell V, Beckett R, Abid N, Hoey S. Resolution of consumptive hypothyroidism secondary to infantile hepatic hemangiomatosis with a combination of propranolol and levothyroxine. JCRPE J Clin Res Pediatr Endocrinol. 2018;10(3):294–8.
Simsek E, Demiral M, Gundoǧdu E. Severe consumptive hypothyroidism caused by multiple infantile hepatic haemangiomas. J Pediatr Endocrinol Metab. 2018;31(7):823–7.
Igarashi A, Hata I, Yuasa M, Okuno T, Ohshima Y. A case of an infant with extremely low birth weight and hypothyroidism associated with massive cutaneous infantile hemangioma. J Pediatr Endocrinol Metab. 2018;31(12):1377–80.
Ahmed Hassan Al-Ghamdi. Consumptive hypothyroidism in a two months old infant secondary to hepatic haemangiomas. Sudan J Paediatr. 2018;18(1):71–5.
Acharya S, Giri PP, Das D, Ghosh A. Hepatic Hemangioendothelioma: A Rare Cause of Congenital Hypothyroidism. Indian J Pediatr. 2019;86:306–7.
Osada A, Araki E, Yamashita Y, Ishii T. Combination therapy of propranolol, levothyroxine, and liothyronine was effective in a case of severe consumptive hypothyroidism associated with infantile hepatic hemangioma. Clin Pediatr Endocrinol. 2019;28(1):9–14.
Yang K, Peng S, Chen L, Chen S, Ji Y. Efficacy of propranolol treatment in infantile hepatic haemangioma. J Paediatr Child Health. 2019;55(10):1194–200.
Kim YH, Lee YA, Shin CH, Hong KT, Kim GB, Ko JS et al. A case of consumptive hypothyroidism in a 1-month-old boy with diffuse infantile hepatic hemangiomas. J Korean Med Sci. 2020;35(22).
Joshi K, Bolia R, Poddar U, Dabadgao P. Consumptive Hypothyroidism Due to Diffuse Hepatic Hemangiomas Treated With Propranolol Therapy. Indian Pediatr. 2020;57:366–8.
Anjali Verma R, Jain, Neha Babbar NPK. Multiple infantile hepatic hemangiomas leading to consumptive hypothyroidism successfully treated with propranolol: A case report. J Family Med Prim Care [Internet]. 2017;6(2):169–70. Available from: http://www.jfmpc.com/article.asp?issn=2249-4863;year=2017;volume=6;issue=1;spage=169;epage=170;aulast=Faizi.
Zheng Z, Li Y, Wang L, Dai C, Qian J, Wang C, et al. Cardiac dysfunction associated with consumptive hypothyroidism in a case of hepatic haemangioma. Endokrynol Pol. 2021;72(4):416–7.
Numazawa M, Tomari K, Igaki J, Koki M, Kina Y, Matsuoka T. Advantages of monitoring rT3 and dividing LT3 dose in the treatment of consumptive hypothyroidism associated with infantile hepatic hemangioma. J Pediatr Endocrinol Metab. 2022;35(11):1453–6.
Morais CG, Alves I, Coelho J, Vilares AT, Do Bom-Sucesso M. Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment. J Pediatr Hematol Oncol. 2023;45(2):E294–7.

Download PDF

Reviewers invited by journal
30 Jul, 2024
Editor assigned by journal
02 Nov, 2023
First submitted to journal
01 Nov, 2023

You are reading this latest preprint version

Consumptive hypothyroidism complicating infantile hepatic hemangioma successfully treated with propranolol: a case report and literature review

Status:

Version 1

Abstract

Figures

BACKGROUND

CASE PRESENTATION

DISCUSSION AND CONCLUSIONS

Abbreviations

Declarations

References

Status:

Version 1